Jennifer Polo

Pharmacokinetics of phosphodiesterase type 5 inhibitors and β-adrenergic receptor type 3 agonists for benign prostatic hyperplasia

Introduction Benign prostatic hyperplasia (BPH) is amongst the most common conditions affecting aging men, with resulting lower urinary tract symptoms (LUTS) impeding on quality of life. While many medication classes exist for treatment of LUTS secondary to BPH, their increasing...